Copy to clipboard 
aap Implantate posted 4Q18 revenue of €2.6MM (USD $3.2MM), -9.8% vs. 4Q17, and full year 2018 revenue of €10.8MM (USD $13.3MM) vs. 2017. After achieving 20% revenue growth in 2017, this year “fell short of expectations” according to company leadership, although it was in line with the guidance of €10MM to €11.7 provided in November 2018. The projections that we published at the end of the third quarter overestimated company performance by 1.9%.
aap performed well in its home market of Germany with 14% year over year growth, as well as in BRIC countries (+32%) and other key European markets (+17%). The company benefitted from traction in major German hospitals and purchasing associations. aap found little success in North America, however, with revenue down -27% vs. 2017, as it was unable to sign new contracts and lost key distributors and clinics.
Leadership is bullish on the company’s 2019 outlook. Its antibacterial silver coating technology produced convincing results in animal studies at the end of 2018, showing no negative influence on bone healing, which is a central requirement for approval. At the end of the year, aap applied to BfArM (Federal Institute for Drugs and Medical Devices) to begin human trials, which are expected to start in 1H19. The company anticipates that human trials, if approved, will increase operating costs and is thus exploring options to strengthen its financial base such as licensing technology and leveraging equity instruments.
aap is targeting 20% – 40% growth in 2019 by focusing on the North American market, exploring strategic partnerships with global orthopaedic companies and expanding its LOQTEQ polyaxial fixation portfolio for the foot and ankle. Leadership provided 2019 guidance in the range of €13MM to €15MM, with 1Q19 revenues between €2MM and €3MM.
4Q18 and FY segment sales and growth on an as-reported basis are as follows.
| 4Q18 | 4Q17 | $ Change | % Change | |
| Trauma | $3.2 | $3.5 | -$0.3 | -9.8% |
| FY18 | FY17 | $ Change | % Change | |
| Trauma | $13.3 | $13.1 | $0.2 | 1.6% |
Source: aap
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
aap Implantate posted 4Q18 revenue of €2.6MM (USD $3.2MM), -9.8% vs. 4Q17, and full year 2018 revenue of €10.8MM (USD $13.3MM) vs. 2017. After achieving 20% revenue growth in 2017, this year “fell short of expectations” according to company leadership, although it was in line with the guidance of €10MM to €11.7 provided in November 2018. The...
aap Implantate posted 4Q18 revenue of €2.6MM (USD $3.2MM), -9.8% vs. 4Q17, and full year 2018 revenue of €10.8MM (USD $13.3MM) vs. 2017. After achieving 20% revenue growth in 2017, this year “fell short of expectations” according to company leadership, although it was in line with the guidance of €10MM to €11.7 provided in November 2018. The projections that we published at the end of the third quarter overestimated company performance by 1.9%.
aap performed well in its home market of Germany with 14% year over year growth, as well as in BRIC countries (+32%) and other key European markets (+17%). The company benefitted from traction in major German hospitals and purchasing associations. aap found little success in North America, however, with revenue down -27% vs. 2017, as it was unable to sign new contracts and lost key distributors and clinics.
Leadership is bullish on the company’s 2019 outlook. Its antibacterial silver coating technology produced convincing results in animal studies at the end of 2018, showing no negative influence on bone healing, which is a central requirement for approval. At the end of the year, aap applied to BfArM (Federal Institute for Drugs and Medical Devices) to begin human trials, which are expected to start in 1H19. The company anticipates that human trials, if approved, will increase operating costs and is thus exploring options to strengthen its financial base such as licensing technology and leveraging equity instruments.
aap is targeting 20% – 40% growth in 2019 by focusing on the North American market, exploring strategic partnerships with global orthopaedic companies and expanding its LOQTEQ polyaxial fixation portfolio for the foot and ankle. Leadership provided 2019 guidance in the range of €13MM to €15MM, with 1Q19 revenues between €2MM and €3MM.
4Q18 and FY segment sales and growth on an as-reported basis are as follows.
| 4Q18 | 4Q17 | $ Change | % Change | |
| Trauma | $3.2 | $3.5 | -$0.3 | -9.8% |
| FY18 | FY17 | $ Change | % Change | |
| Trauma | $13.3 | $13.1 | $0.2 | 1.6% |
Source: aap
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
